Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03433469 · ClinicalTrials.gov registry record · Phase 2
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
A Phase 2 study of Stage IIIA Non-Small Cell Lung Cancer and Stage I Non-Small Cell Lung Cancer, sponsored by University of California, San Francisco.
- Active
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 3
- Study locations
NCT03433469: Active Phase 2 study of Stage IIIA Non-Small Cell Lung Cancer and Stage I Non-Small Cell Lung Cancer, sponsored by University of California, San Francisco.
NCT03433469 is a Phase 2 study of Stage IIIA Non-Small Cell Lung Cancer and Stage I Non-Small Cell Lung Cancer that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 27 participants, below the 33-participant average among 10 other Stage IIIA Non-Small Cell Lung Cancer trials with a reported enrollment target (18% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03433469, a Phase 2 study of Stage IIIA Non-Small Cell Lung Cancer and Stage I Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before surgery. Osimertinib may stop the growth of tumor cells by blocking mutant EGFR signaling in cancer cells.
Primary Outcome
Tumors that exhibit =\< 10% viable tumor will meet the criteria for a major pathological response. MPR will be determined in patients who receive at least one dose of study drug and become ineligible for surgery either because of disease progression or adverse event will be deemed not to have achieved MPR. The major pathological response rate will be reported with 95% confidence intervals.
Conditions Studied
Interventions
- DRUG Osimertinib
- PROCEDURE Therapeutic Conventional Surgery
Study Locations (3)
California
- University of California, Davis - Davis
- University of California, San Francisco - San Francisco
Colorado
- University of Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 2 |
What the registry record for NCT03433469 still lists
NCT03433469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 33-participant average among 10 other Stage IIIA Non-Small Cell Lung Cancer trials with a reported enrollment target (18% lower).
The record links to 7 conditions, with Stage IIIA Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib is the first listed.
NCT03433469 reports a single indexed study location in California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03433469 about?
NCT03433469 is a clinical study titled "Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery". This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before surgery. Osimertinib may stop the growth of tumor cells by blocking mutant EGFR signaling in cancer cells.
What is the current status of trial NCT03433469?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2018-07-31. Estimated completion is 2026-10-31.
What conditions does trial NCT03433469 study?
This clinical trial studies the following conditions: Stage IIIA Non-Small Cell Lung Cancer, Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03433469?
The interventions under investigation include: Osimertinib (DRUG), Therapeutic Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT03433469?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03433469 being conducted?
This trial has 3 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIIA Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03433469's enrollment target sits among peer trials
27 6th of 10 higher than 5 of 10 other Stage IIIA Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IIIA Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
18F-FSPG PET/CT for Cancer Patients on Therapy
COMPLETED · Phase 2
-
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
COMPLETED · Phase 2
-
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
ACTIVE NOT RECRUITING · NA
-
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI